Dapagliflozin’s impact on hormonal regulation and ketogenesis in type 1 diabetes: a randomised controlled crossover trial
Authors' conclusion
Short-term dapagliflozin treatment in type 1 diabetes increases plasma ketone concentrations without affecting the secretion of GLP-1, glucagon or somatostatin. Higher ketone body concentrations highlight the elevated risk of diabetic ketoacidosis associated with the adjunct intake of dapagliflozin.
Study context
- Population
- T1D (C-peptide <0.1 nmol/l), duration >5 years, BMI 20–29 kg/m²; Inselspital, Bern University Hospitalall analysed per protocol
- Participants
- 13 participants
- Comparison
- Dapagliflozin 10 mg daily added to insulin vs placebo
- Primary endpoint
- GLP-1 concentrations during OGTT clamp (OGTTC)
- Follow-up
- Day 7 of each treatment period
Methodological detailsplacebo-controlled, open-label, two 7-day periods, 14-day washout
- Placebo-controlled
- Open-label
- Two 7-day periods, 14-day washout
Primary result
As reported in the abstract
P = 0.7
Secondary outcomes
GLP-1 during HEC · day 7 · did not differ significantly
P = 0.7
Somatostatin during HEC · day 7 · comparable
P = 0.2
Somatostatin during OGTTC · day 7 · comparable
P = 0.2
Glucagon during OGTTC · day 7 · did not differ significantly
P = 0.8
Glucagon during HEC · day 7 · did not differ significantly
P = 0.3
Plasma ketone bodies during HEC · day 7 · higher with dapagliflozin
P < 0.001
Plasma ketone bodies during OGTTC · day 7 · higher with dapagliflozin
P < 0.001
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →